EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The role of traditional NSAIDs and selective COX-2 inhibitors on COVID-19 outcomes: a real-world data study

Narmeen Mallah, Irene Visos-Varela, Bahi Takkouche, Rosendo Bugarín-González, María Piñeiro-Lamas, Teresa Herdeiro, Maruxa Zapata-Cachafeiro, Almudena Rodríguez-Fernández, Angel Salgado-Barreira, Adolfo Figueiras, COVIDrug Group

Inflammopharmacology · 2024

DOI: 10.1007/s10787-024-01568-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammopharmacology, 2024. Verfasst von Narmeen Mallah und 10 weiteren Autor:innen. Beteiligte Einrichtung: Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Institute of Health Research of Santiago de Compostela de Compostela, S…. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Cyclooxygenase 2 Inhibitors, COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The relation between use of nonsteroidal anti-inflammatory drugs (NSAIDs) and severity of COVID-19 has been the subject to debate since the outbreak of the pandemic. Despite speculations about the possible harmful or protective effects, the position currently most supported by the scientific community is that there is no association between use of NSAIDs and COVID-19 outcomes. With the aim of contributing to increase the body of evidence on this issue, we conducted a case-control study using real-world data to investigate the association between prior use of NSAIDs, by active ingredient and type (traditional NSAIDs and selective COX-2 inhibitors), and important COVID-19-related outcomes, including susceptibility, PCR + patient progression, and hospitalisation. Our findings suggest that, in general, the use of traditional NSAIDs is not associated with any adverse COVID-19 outcome. However, we observed a possible association between diclofenac and a higher risk of PCR + patient progression. Our results also suggest that selective COX-2 inhibitors might be related with a reduction in the risk of PCR + patient progression. These results suggest that, with the possible exception of diclofenac, the use of NSAIDs should not be advised against for relief of symptoms in patients with COVID-19. In addition, they support the importance of continue to investigate the treatment potential of selective COX-2 inhibitors in the management of COVID-19, something that could have significant implications for the treatment of this disease and other viral infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Inflammatory Agents, Non-SteroidalCyclooxygenase 2 InhibitorsCOVID-19HumansCase-Control StudiesMaleFemaleMiddle AgedAgedCOVID-19 Drug TreatmentHospitalizationDiclofenacDisease ProgressionSARS-CoV-2

Stichwörter der Autor:innen

COVID-19HospitalisationNon-steroidal anti-inflammatory agentsReal world-dataSusceptibility

Substanzen

Anti-Inflammatory Agents, Non-SteroidalCyclooxygenase 2 InhibitorsDiclofenac

Autor:innen und Institutionen

  • Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Institute of Health Research of Santiago de Compostela de Compostela, Santiago de Compostela, Spain.
  • WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain.
  • Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología y Salud Pública-CIBERESP), Madrid, Spain.
  • Department of Preventive Medicine and Public Health, University of Santiago de Compostela, C/ San Francisco s/n, 15782, Santiago de Compostela, Spain.
  • Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Institute of Health Research of Santiago de Compostela de Compostela, Santiago de Compostela, Spain. irene.visos.varela@usc.es.
  • WHO Collaborating Centre for Vaccine Safety, Santiago de Compostela, Spain. irene.visos.varela@usc.es.

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Mallah, N., Visos-Varela, I., Takkouche, B., Bugarín-González, R., Piñeiro-Lamas, M., Herdeiro, T., Zapata-Cachafeiro, M., Rodríguez-Fernández, A., Salgado-Barreira, A., Figueiras, A., & COVIDrug Group (2024). The role of traditional NSAIDs and selective COX-2 inhibitors on COVID-19 outcomes: a real-world data study. Inflammopharmacology. https://doi.org/10.1007/s10787-024-01568-y

Vancouver

Mallah N, Visos-Varela I, Takkouche B, Bugarín-González R, Piñeiro-Lamas M, Herdeiro T, et al. The role of traditional NSAIDs and selective COX-2 inhibitors on COVID-19 outcomes: a real-world data study. Inflammopharmacology. 2024. doi:10.1007/s10787-024-01568-y

BibTeX
@article{Mallah2024,
  author = {Mallah, Narmeen and Visos-Varela, Irene and Takkouche, Bahi and Bugarín-González, Rosendo and Piñeiro-Lamas, María and Herdeiro, Teresa and Zapata-Cachafeiro, Maruxa and Rodríguez-Fernández, Almudena and Salgado-Barreira, Angel and Figueiras, Adolfo and COVIDrug Group, COVIDrug Group},
  title = {The role of traditional NSAIDs and selective COX-2 inhibitors on COVID-19 outcomes: a real-world data study},
  journal = {Inflammopharmacology},
  year = {2024},
  doi = {10.1007/s10787-024-01568-y}
}
Kostenlos starten →